Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman, R.; Thase, Michael E.; Trivedi, Madhukar H.; Hazel, James A; Marler, Sabrina; McQuade, Robert D.; Carson, William H.; Baker, Ross A.; Marcus, Ronald N.

doi:10.2147/ndt.s18333

Cited by 45 publications

(61 citation statements)

References 23 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when we consider that the duration of most trials varied from 4 to 12 weeks, such short-term trial duration may not accurately evaluate a potential development of TD in patients with MDD. Currently, we have only two 52-week maintenance studies each in aripiprazole and quetiapine XR for MDD [50,51]. There were four spontaneous reports of TD in aripiprazole's 52-week longterm study, although all four cases resolved with dose reduction or drug discontinuation.…”

Section: Clinical Issues In the Use Of Atypical Antipsychotics In CLImentioning

confidence: 99%

Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients

Pae

Patkar

2013

CNS Drugs

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not respond to initial antidepressant treatment. The existing literature demonstrates that augmentation with atypical antipsychotics (AAs) shows higher response and remission rates compared with antidepressant monotherapy, but is associated with more withdrawals due to adverse events. In this paper, specific clinical issues in the use of AA augmentation for patients with MDD are briefly discussed. Given the limited information and clinical knowledge on the proper and effective use of AAs for MDD, future research should focus on practical clinical issues that can be commonly seen in routine practice but have not been addressed yet. This is because the use of AAs is likely to expand as there is good evidence for their effectiveness and tolerability as augmentation therapy for patients with MDD.

show abstract

Section: Clinical Issues In the Use Of Atypical Antipsychotics In CLImentioning

confidence: 99%

Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients

Pae

Patkar

2013

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…Although clinical experience is limited during longer-term adjunctive therapy, there is reason to be optimistic that dyskinesias will resolve if the offending medication is stopped. 22 …”

Section: Recommendations To Minimize Riskmentioning

confidence: 99%

Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants

Thase

2016

Psychiatric Clinics of North America

View full text Add to dashboard Cite

“…One study reported the longer-term tolerability of adjunctive aripiprazole treatment in an open-label 52-week trial with 994 patients [14]. …”

Section: Aripiprazolementioning

confidence: 99%

Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression

Kato

Chang

2013

CNS Drugs

View full text Add to dashboard Cite

Various classes of antidepressants have been used in the treatment of major depressive disorder (MDD); however, the efficacy of these treatments remains uncertain. A number of well-controlled clinical trials, meta-analyses and practical clinical studies have found that approximately 30 % of MDD patients remit following antidepressant treatment, leaving approximately 70 % of patients with significant residual symptoms. In these latter patients with what is considered treatment-resistant MDD, typical antipsychotics have sometimes been administered in order to augment the antidepressant effects but safety and tolerability concerns significantly reduce their usage in MDD patients. The advent of second-generation antipsychotics (SGAs), which have diverse pharmacodynamic profiles relative to antidepressants, has dramatically increased the usage of such drugs for patients with MDD. Recently, SGAs such as aripiprazole, quetiapine and olanzapine in combination with fluoxetine have been approved for the treatment of MDD, especially in the case of treatment resistance. This article reviews the efficacy and tolerability of SGA augmentation when added to antidepressant therapy for treatment-resistant MDD patients in acute phase studies published to date.

show abstract

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Cited by 45 publications

References 23 publications

Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients

Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients

Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants

Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression

Contact Info

Product

Resources

About